Argeris (Jerry) N. Karabelas, Ph.D.

Chairman of the Board since October 2004 and Member since 2002

Argeris (Jerry) N. Karabelas is Chairman of the Board and a member of the Compensation Committee. He has been a partner of Care Capital LLC since 2001 and was the Founder and Chairman of Novartis BioVenture Fund from 2000 to 2001. Dr. Karabelas was also the Head of Healthcare and CEO of Worldwide Pharmaceuticals at Novartis, AG from 1998 to 2000; Executive Vice President, Pharmaceuticals, at SmithKline Beecham from 1997 to 1998; President, North American Pharmaceuticals, at SmithKline Beecham from 1993 to 1997; and Vice President, U.S. Marketing, at SmithKline Beecham from 1990 to 1993. Dr. Karabelas is a Visiting Committee Member of MIT Health Studies & Technology, Director of SkyePharma PLC, Chairman of Nitromed, Inc., Director of Cyreniac Pharmaceutical, Director of Minster Pharmaceuticals plc; Director of Renovo PLC, Chairman of Vanda Pharmaceuticals Inc. and Chairman of Inotek, Inc.

H. Thomas Watkins

President and Chief Executive Officer, and Member since 2004

H. Thomas Watkins joined HGS as Chief Executive Officer and a Director of the Company in November 2004, and in December 2005 added the title of President. Mr. Watkins came to HGS with nearly twenty years of experience at Abbott Laboratories and its affiliates in the U.S. and Asia. From 1998 to 2004, he served as President of TAP Pharmaceutical Products Inc., which is jointly owned by Abbott Laboratories and Takeda Pharmaceutical Company Limited. Mr. Watkins joined Abbott in 1985 and held various executive positions in the Pharmaceutical Products Division, Diagnostics Division and HealthSystems Division prior to joining TAP in 1998. He was elected a corporate officer of Abbott in December 1996, while serving as Vice President, Diagnostic Operations, Asia and Pacific. Mr. Watkins holds a bachelor’s degree from The College of William and Mary, and a master’s degree in business administration from the University of Chicago Graduate School of Business. He is a member of the Board of Directors of Vanda Pharmaceuticals, Inc. and the U.S. Chamber of Commerce, and a member of the Health Section Governing Body of the Biotechnology Industry Organization (BIO). Mr. Watkins serves as a Trustee of The College of William and Mary Foundation and as a member of the Foundation Board of Trustees of The Mason School of Business of The College of William and Mary. He is a member of the Board of Visitors of the University of Maryland Biotechnology Institute. Mr. Watkins also currently serves as Chair of the Life Sciences Advisory Board of the State of Maryland.

Richard J. Danzig

Member since 2001

Richard Danzig is a member of the Audit Committee. He serves as a consultant to U.S. Government Departments and Agencies on biological terrorism. He is a Nunn Prize Fellow at the Center for Strategic and International Studies and Senior Fellow at the Center for Naval Analyses and the Center for a New American Security. Mr. Danzig is also a member of the U.S. Military Southern Command Advisory Board. He serves on the boards of directors of National Semiconductor Corporation and Saffron Hill Ventures, the Center for a New American Security and the Partnership for Public Service. He served as Secretary of the Navy from 1998 to 2001 and as Under Secretary of the Navy from 1993 to 1997. He was a Traveling Fellow of the Center for International Political Economy and an Adjunct Professor at Syracuse University's Maxwell School of Citizenship & Public Affairs between 1997 and 1998. He was a partner in the law firm of Latham and Watkins from 1981 to 1993.

Jürgen Drews, M.D.

Member since 1998

Dr. Jürgen Drews is a member of the Nominating and Governance Committee. Dr. Drews served as Chairman and Partner of International Biomedicine Management Partners in Basel, Switzerland, from 1997 to 2001. He was Managing Partner of Bear Stearns Health Innoventures from 2001 to 2004 and a member of the Executive Committee of the Roche Group, Hoffman-La Roche, Inc. from 1986 until his retirement in 1998. Dr. Drews also served as President of Global Research for the Roche Group from 1996 to 1998. He was President of International Research and Development at the Roche Group from 1991 to 1996. Before joining Roche in 1985, Dr. Drews was Head of International Pharmaceutical Research and Development of Sandoz, Ltd. in Basel, Switzerland. Dr. Drews serves as Chairman of the Board of Directors of GPC-biotech AG and is a Director of MorphoSys GmbH, both in Munich, Germany.

Maxine Gowen, Ph.D.

Member since February 2008

Dr. Maxine Gowen is President and Chief Executive Officer of Trevena, Inc., a privately held drug discovery company. Prior to joining Trevena, Dr. Gowen was Senior Vice President of GlaxoSmithKline’s Center of Excellence for External Drug Discovery. In that position, she built and led a new division with a mission to create a drug discovery portfolio through business development alliances with innovative healthcare companies. She was with GSK for 15 years, where she held a series of executive management positions in drug discovery and development and led the GSK venture capital subsidiary, S.R. One. Before GSK, Dr. Gowen was Senior Lecturer and Head, Bone Cell Biology Group, Department of Bone and Joint Medicine, University of Bath, U.K. Dr. Gowen has been honored with a number of research awards and prizes, has authored more than 125 peer-reviewed publications, reviews and book chapters, and holds five patents. She received her Ph.D. from the University of Sheffield, U.K., an M.B.A. with academic honors from The Wharton School of the University of Pennsylvania, and a B.Sc. with Honors in Biochemistry from the University of Bristol, U.K.

Tuan Ha-Ngoc

Member since 2005

Tuan Ha-Ngoc is a member of the Audit Committee and the Nominating and Governance Committee. Mr. Ha-Ngoc is President and CEO of AVEO Pharmaceuticals, Inc., a privately held biopharmaceutical company focused on the discovery and development of novel cancer therapeutics. From 1999 to 2002, he was co-founder, President and CEO of deNovis, Inc., an enterprise-scale software development company for the automation of healthcare administrative functions. From 1998 to 1999, Mr. Ha-Ngoc was Corporate Vice President of Strategic Development for Wyeth, following Wyeth's acquisition of Genetics Institute, where Mr. Ha-Ngoc served as Executive Vice President with responsibility for Corporate Development, Commercial Operations, European and Japanese Operations. Prior to joining Genetics Institute in 1984, Mr. Ha-Ngoc held various marketing and business positions at Baxter Healthcare, Inc. He received his MBA degree from INSEAD and his Master's degree in pharmacy from the University of Paris, France. Mr. Ha-Ngoc serves on the Board of Directors of AVEO Pharmaceuticals, Inc., and on the boards of a number of academic and nonprofit organizations, including the Harvard School of Dental Medicine, the Tufts School of Medicine, the Belmont Hill School, the Boston Philharmonic Orchestra and the International Institute of Boston.

Augustine Lawlor

Member since 2004

Augustine Lawlor is Chair of the Audit Committee and a member of the Compensation Committee. Mr. Lawlor is the Managing Partner of HealthCare Ventures LLC. Prior to joining HealthCare Ventures in 2000, Mr. Lawlor served as Chief Operating Officer of LeukoSite from 1997 to 2000. Before joining LeukoSite, Mr. Lawlor served as Chief Financial Officer and Vice President of Corporate Development of Alpha-Beta Technology. He was previously Chief Financial Officer and Vice President, Business Development, of BioSurface Technology. Mr. Lawlor serves on the Boards of Directors of a number of private companies, including Catalyst; Dynogen Pharma, Inc.; GlobeImmune, Inc.; FoldRx Pharmaceuticals, Inc.; Replidyne, Inc.; Promedior, Inc; Synovex; U.S. Genomics, Inc.; VaxInnate, Corp.; and the Slater Center for Biomedical Technology. He received a B.A. degree from the University of New Hampshire, where he was elected to Phi Beta Kappa, and received a Master’s degree in management from Yale University.

Max Link, Ph.D.

Member since 1995

Dr. Max Link is Chair of the Compensation Committee. Dr. Link has held a number of executive positions with pharmaceutical and healthcare companies. From March 2001 to September 2003, he served as Chairman and subsequently CEO of Centerpulse, Ltd. (previously Sulzer Medica). He served as Chief Executive Officer of Corange Limited from May 1993 to June 1994. Prior to joining Corange Limited, Dr. Link held a number of positions within Sandoz Pharma Ltd., including Chief Executive Officer from 1987 to April 1992, and Chairman from April 1992 to May 1993. Dr. Link is currently Chairman of the Boards of Directors of Alexion Pharmaceuticals, Inc.; Celsion Corporation; CytRx; and PDL Biopharma. He serves on the Board of Directors of Discovery Laboratories, Inc. Dr. Link received his doctorate in economics from the University of St. Gallen.

Robert C. Young, M.D.

Member since 2005

Dr. Robert Young is Chair of the Nominating and Governance Committee. Dr. Young is Chancellor of Fox Chase Cancer Center in Philadelphia, Pennsylvania, and formerly served as President of Fox Chase from 1988 to 2007. From 1974 to 1988, he was employed at the National Cancer Institute as Chief of the Medical Branch. Dr. Young is Chairman of the Board of Scientific Advisors of the National Cancer Institute (NCI) and formerly served on the National Cancer Policy Board at the Institute of Medicine. He is a past President of the American Society of Clinical Oncology (ASCO), the American Cancer Society and the International Gynecologic Cancer Society. He was awarded ASCO’s Distinguished Service Award for Scientific Leadership in 2004 and was co-recipient of the 2002 Bristol-Myers Squibb Award for Distinguished Achievement in Cancer Research for his research in ovarian cancer. He also serves on the Board of Directors of West Pharmaceutical Services, Inc. and is a past Chairman of the Comprehensive Cancer Network. Dr. Young serves as chairman of the editorial board of Oncology Times. Dr. Young received his B.Sc. degree in zoology in 1960 from Ohio State University and his M.D. in 1965 from Cornell University Medical College. Following his internship at New York Hospital, he completed his residency at NCI and Yale-New Haven Medical Center. He is board-certified in internal medicine, hematology and oncology by the American Board of Internal Medicine.